Compare Ecolab Inc. (ECL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Zoetis Inc — how do they compare? Ecolab Inc. trades at $281.97 (market cap $78.97B), while Zoetis Inc trades at $74.33 (market cap $30.20B). The key difference: Ecolab Inc. is far larger — about 2.6× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and Zoetis Inc for 70 Days on average.
| ECL | ZTS | |
|---|---|---|
Market Cap | $78.97B | $30.20B |
Volume | 974,947 | 6,175,327 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $147.53 |
52-Week Low | $245.73 | $69.09 |
Typical Hold Time | 90 Days | 70 Days |
Enterprise Value | $87.75B | $37.76B |
Dividend Yield | 1.04% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $278.10, down 0.97% on the day, with strong analyst support (78% buy ratings) and a $326.38 consensus price target suggesting 17% upside. The stock shows bullish technical signals with support at $275 and resistance at $279. Recent Q2 2026 earnings beat expectations with 9.7% sales growth, while the company maintains dividend aristocrat status with consistent payout increases.
ECL presents a compelling growth story with expanding high-tech and digital segments, though elevated valuation multiples (P/E 37.81) and rising debt from the CoolIT acquisition warrant caution. The essential nature of its hygiene and water management services provides defensive characteristics, while upcoming Q3 earnings on October 27 will be critical for validating growth trajectory.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
